Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the...
Buyer
NHS England
Value
£142,512,000
Published
16 Jan 2026
Closes
13 Oct 2025
Procurement details
Source
Find a Tender
Region
United Kingdom
Procurement method
Open
Category
Services
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
85100000
Health services
Lots
Lot 1 Lot 1 - London
£142,512,000
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: United Kingdom, London
Lot 2 Lot 2 - East of England
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: East Of England
Lot 3 Lot 3: South East
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: South East (England)
Lot 4 Lot 4: South West
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: South West (England)
Lot 5 Lot 5: Midlands
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: East Midlands (England), West Midlands (England)
Lot 6 Lot 6: North East & Yorkshire
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: North East (England), Yorkshire And The Humber
Lot 7 Lot 7: North West
Value not provided
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autol...
Delivery: North West (England)
Documents
No document metadata is available for this public record.
Contains public sector information licensed under the Open Government Licence v3.0.